Ceva Animal Health appoints Sébastien Huron as Deputy Chief Executive Officer
LIBOURNE, France, April 10, 2026 /PRNewswire/ -- Ceva Animal Health, the world's fifth largest animal health company, majority-owned by its management team, today announces the appointment of Sébastien Huron as Deputy Chief Executive Officer, effective immediately. This move forms part of a broader governance evolution, following Marc Prikazsky's decision to appoint a...
NovogeneAIT Genomics Appointed as Service Provider to Advance Large-Scale Proteomics for PRECISE-SG100K Cohort in Singapore
SINGAPORE, April 10, 2026 /PRNewswire/ -- NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by Thermo Fisher Scientific in collaboration with PRECISE to support precision medicine research in Singapore. This landmark project will utilize Thermo...
Tairex Launches Virtual Consultation Room, Setting A New Paradigm for AI Medical Services
BEIJING, April 10, 2026 /PRNewswire/ -- Wuxi Tairex Technology Co. Ltd. ("Tairex" or the "Company") today announced the launch of the Virtual Consultation Room for Tairex Agent Hospital, now open to doctors and medical students. Built on Tairex Agent Hospital, a virtual medical world centered on AI agents, the new feature provides a scalable environment for simulated clinical...
ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza infection, following approval by the Human Research Ethics Committee (HREC)...
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision — a program that recently delivered landmark wins in...
No More Seasonal Blues! iHerb Launches Spring “Defense-Focused” Health Guide: Discovering 6 Nutritional Essentials
HONG KONG, April 10, 2026 /PRNewswire/ -- As spring arrives, drastic changes in temperature and environmental humidity often lead to "seasonal discomforts" such as fatigue and disrupted routines. Recognizing the rising demand for spring skincare and nutritional supplements, global cross-border health e-commerce platform iHerb has launched the "Spring Defense Supplement Guide." It features 6 cost-effective health products, ranging from daily...
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 10, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund....
Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA
SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis (AD), has been formally accepted by the...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company's resubmitted New Drug Application (NDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging...
INTRODUCING NATURE’S WELLNESS SANCTUARY AT 1 HOTEL HANALEI BAY
A Next-Generation Wellness Destination on the North Shore of Kauaʻi KAUAʻI, Hawaiʻi, April 10, 2026 /PRNewswire/ -- 1 Hotel Hanalei Bay announces the debut of Nature's Wellness Sanctuary, a trailblazing wellness concept on the North Shore of Hawaiʻi's most magical island, the Garden Island of Kauaʻi. Opened in 2023, 1 Hotel...
